BRAF and neutropenia: In this setting, it is of utmost importance to improve the molecular characterization, in order to identify new targets for the identification of new biology-driven therapeutic approaches that present a manageable toxicity and reduce secondary incidence of neutropenia, such as vemurafenib, a BRAF kinase inhibitor we used in the treatment of LCH with negligible adverse effects [16].